Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Goldman Sachs Reinstates ColgatePalmolive with Buy Rating and 93 Price Target

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
GD stock news
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter

Goldman Sachs analyst Jason English has reinstated Colgate-Palmolive (NYSE: CL) with a Buy rating and a price target of $93, signaling optimism about the company’s future performance and stock value. This decision underscores Goldman Sachs’ confidence in Colgate-Palmolive’s outlook and financial well-being.

The reinstatement by Goldman Sachs is in line with Colgate-Palmolive’s recent financial activities, including adjustments to goodwill values in SEC filings. These adjustments are standard practices to ensure accurate financial reporting and valuation.

Additionally, Goldman Sachs’ decision to reinstate Colgate-Palmolive reflects a strategic move based on the company’s market performance and conditions. It serves as a recommendation to investors to consider purchasing Colgate-Palmolive stock at its current price, with the potential for it to reach $93 per share according to the price target set by Goldman Sachs.

Overall, Goldman Sachs’ reinstatement of Colgate-Palmolive with a Buy rating and $93 price target signifies a positive evaluation of the company’s growth prospects and financial stability, offering valuable guidance to investors interested in this stock.

Colgate-Palmolive Company (CL) Stock Price Drops Slightly on March 1, 2024: What Investors Need to Know

On March 1, 2024, Colgate-Palmolive Company (CL) experienced a slight decrease in its stock price. The price of CL shares decreased by $0.31 since the market last closed, representing a 0.35% drop. The stock closed at $86.52 on the previous trading day. In pre-market trading on March 1, the stock dropped an additional $0.32.

Colgate-Palmolive Company is a well-established consumer goods company with a strong track record of success. Investors should also consider factors such as market trends, industry news, and company announcements when evaluating the performance of a stock. It’s always recommended to conduct thorough research and consult with a financial advisor before making any investment decisions.

Overall, the slight drop in CL’s stock price on March 1 should be viewed in the context of the broader market and the company’s overall performance. It’s important for investors to stay informed and make decisions based on a comprehensive analysis of all available information.

CL Corporation Stock Price Rises on Strong Financial Results for March 1, 2024

CL Corporation had a strong performance on March 1, 2024, as its stock price showed positive movement following the release of its financial results. According to data from CNN Money, the company reported total revenue of $19.46 billion for the past year, with a quarterly revenue of $4.95 billion. Net income for CL Corporation was reported at $2.30 billion for the past year, with a quarterly net income of $718.00 million. Earnings per share (EPS) for the company were $2.77 for the past year, with a quarterly EPS of $0.87. Investors reacted positively to CL Corporation’s financial results, as the stock price showed an upward trend on March 1, 2024. The strong performance in total revenue, net income, and EPS indicates that the company is on a solid growth trajectory. Overall, CL Corporation’s stock performance on March 1, 2024, reflects the company’s strong financial performance and positive outlook for future growth. Investors can be optimistic about the company’s potential for continued success based on its solid financial results.

Tags: CL
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Financings on laptop

Unveiling the Latest Trends in Broad-Spectrum Commodity Pricing Intelligence

Finance_Assets (3)

Utz Brands Analyst Scoreboard Recent Ratings and Price Targets

Empowering the Next Generation enCore Energys Education Society and Scholarship Programs

Recommended

FCBC stock news

Impax Asset Management Group plc Reduces Stake in Snap Inc. as Insiders Sell Off Shares

2 years ago
The Trade Desk Stock

The Trade Desk: A Market Conundrum of Conflicting Signals

3 months ago
Intel Stock

US Government Holds Massive Intel Share Position, Creating Market Uncertainty

5 months ago
Nuvalent Stock

Nuvalent Shares Surge on Promising Clinical Trial Results

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

DroneShield Shares Face Headwinds Despite Record Performance

Rock Tech Lithium: Investors Await the Final Go-Ahead

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Trending

KemPharm Stock
Analysis

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

by Kennethcix
February 8, 2026
0

Zevra Therapeutics continues to build its profile as a dedicated rare disease company. Recent clinical data presentations...

Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026
SuRo Capital Stock

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026
Chicago Atlantic Real Estate Finance Stock

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

February 8, 2026
RBB Stock

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion
  • Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit
  • SuRo Capital Sharpens Focus on AI Infrastructure Investments

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com